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Abstract
Background: In Human African Trypanosomiasis, neurological symptoms dominate and cardiac involvement has been
suggested. Because of increasing resistance to the available drugs for HAT, new compounds are desperately needed.
Evaluation of cardiotoxicity is one parameter of drug safety, but without knowledge of the baseline heart involvement in
HAT, cardiologic findings and drug-induced alterations will be difficult to interpret. The aims of the study were to assess the
frequency and characteristics of electrocardiographic findings in the first stage of HAT, to compare these findings to those
of second stage patients and healthy controls and to assess any potential effects of different therapeutic antiparasitic
compounds with respect to ECG changes after treatment.
Methods: Four hundred and six patients with first stage HAT were recruited in the Democratic Republic of Congo, Angola
and Sudan between 2002 and 2007 in a series of clinical trials comparing the efficacy and safety of the experimental
treatment DB289 to the standard first stage treatment, pentamidine. These ECGs were compared to the ECGs of healthy
volunteers (n=61) and to those of second stage HAT patients (n=56).
Results: In first and second stage HAT, a prolonged QTc interval, repolarization changes and low voltage were significantly
more frequent than in healthy controls. Treatment in first stage was associated with repolarization changes in both the
DB289 and the pentamidine group to a similar extent. The QTc interval did not change during treatment.
Conclusions: Cardiac involvement in HAT, as demonstrated by ECG alterations, appears early in the evolution of the disease.
The prolongation of the QTC interval comprises a risk of fatal arrhythmias if new drugs with an additional potential of QTC
prolongation will be used. During treatment ECG abnormalities such as repolarization changes consistent with peri-
myocarditis occur frequently and appear to be associated with the disease stage, but not with a specific drug.
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Introduction
Human African Trypanosomiasis (HAT) or sleeping sickness
evolves in two stages, the first or early (hemo-lymphatic) stage and
the second or late (meningo-encephalitic) stage which is charac-
terized by invasion of the central nervous system (CNS) by
trypanosomes. Neuropsychiatric disturbances are the most prom-
inent and best documented features of the disease [1]. Cardiac
involvement plays an important role in American trypanosomiasis
(Chagas’ disease); however, in the African form, cardiac
involvement has been suggested but has never been studied
systematically in the first stage of the disease. Cardiac involvement
has been observed in up to 73% of HAT patients in post mortem
histological studies [2,3]. Those findings are supported by the
recent study of Blum et al [4] that showed cardiac alterations in
71% of second stage HAT patients, but are in contrast to previous
studies, where ECG findings were reported in only 35–48% of the
patients [5–7]. The latter studies included both first and second-
stage HAT patients. A low prevalence of ECG findings in first
stage disease could explain this discrepancy. Thus, cardiac
www.plosntds.org 1 February 2009 | Volume 3 | Issue 2 | e383involvement, as documented by ECG findings, may parallel CNS
involvement and ECG findings could be used as additional tool for
assessing the advancement of the disease.
Because of increasing resistance to the available drugs for HAT,
new compounds or drug combinations are desperately needed.
Evaluation of cardiotoxicity and the risk of cardiac arrhythmia is
one parameter of drug safety, but without knowledge of heart
involvement in HAT, cardiologic findings and drug-induced ECG
alterations will be difficult to interpret.
Pentamidine administered intramuscularly is currently the
primary treatment for first stage HAT. A large number of
diamidine compounds have been synthesized in an attempt to
develop an oral agent for this disease. DB289 (pafuramidine
maleate) is one of these diamidine compounds. It can be orally
administered and showed good efficacy against first stage HAT in
Phase II trials. Since diamidines such as pentamidine have been
shown to have arrhythmic potential [8], knowledge of HAT
cardiopathy and scrupulous analysis of the potential cardiac effects
of new antiparasitic drugs is essential.
The overall aim of the study was to assess the cardiac
involvement in first stage HAT by ECG examination and to
study the effect of different antiparasitic drugs on ECG findings.
Methods
Objectives
The objectives of this study were to assess the frequency and
character of ECG findings in patients with first stage HAT and to
compare them to healthy control subjects and to second stage
HAT patients. Secondary objectives were to assess differences
between administered HAT therapies, including ECG changes
during and after treatment, and to discuss the findings with respect
to clinical relevance and tolerability of medical therapy.
Criteria of selection of trials
The objectives were to study and characterize ECG alterations
in T.b. gambiense patients with respect to the stage of the disease
(first versus second stage) and treatment induced alterations
(baseline versus after treatment).
Only studies with clear definition of ECG criteria and complete
ECG description (including QTc intervals), description of the stage
of the disease and ECG before and after treatment were included.
Using these criteria the following studies were not included:
N Studies on ECG alterations of patients infected with T.b.
rhodesiense [9–11]
N Studies without indication, in which stage the patient was [5–
7,12,13]
N Studies without ECG at baseline and after treatment
alterations [3,6,7,12,13]
N Studies without clear inclusion/exclusion criteria or definition
of ECG
# Unclear, why only 28/100 patients had an ECG [3]
# ECG description vague and no indication of QTc [5–
7,13,14]
Participants
Electrocardiograms (ECG) were performed prior to and
following treatment and analyzed in a total of 523 participants;
406 were patients with first stage HAT, 56 with second stage HAT
and 61 were healthy controls. Patients and controls from different
clinical trials are included in the present analysis.
Firststagepatients. First stage HAT patients were recruited in
the frame of phase II & III trials (International Standard Randomised
Controlled Trial Number Register: ISRCTN85534673, 289-C-003
NCT 00802594, 289-C-006 NCT 00803933) conducted for the
development of DB289 (pafuramidine maleate) in the Democratic
Republic of Congo (Maluku, Vanga, Kikongo, Bandundu), Angola
(Uı ´ge) and Sudan (Yei). Between April 2002 and March 2007 a total
of 415 patients older than 12 years were enrolled in these trials and
406 of them had sufficient ECG and treatment data to be included in
this analysis. 177 patients received pentamidine (4 mg/kg daily) for 7
consecutive days by intramuscular injection. 64 patients received oral
DB289 (200 mg total daily dose, divided twice daily) for 5 days and
165 patients had oral DB289 (200 mg total daily dose, divided twice
daily) for 10 days.
Second stage patients and healthy controls. 59
consecutive patients older than 15 years with parasitologically
confirmed second stage HAT were enrolled in a separate
prospective cohort study [4]. Three patients died either before
or during treatment and were excluded from the current analysis.
The control group consisted of 61 healthy persons with no
previous history of HAT, matched for gender and age (+/25
years). Data were collected between July 2004 and September
2005 in the DRC at the University Clinic in Kinshasa (Centre
Neuro Psycho Pathologique), and at the Ho ˆpital Evange ´lique de
Vanga, Bandundu. Melarsoprol was the treatment of first line in
patients with stage II HAT, 18 patients got melarsoprol
intravenously (2.2 mg/kg/day) for 10 consecutive days [15] and
29 patients received the standard melarsoprol treatment [16] of
increasing doses in 3 series of 3 days with rest periods of 7 days
between the series. Eflornithine was reserved for patients with
clinically advanced disease or after treatment failure with
melarsoprol; 9 patients received eflornithine (400 mg/kg/day)
via intravenous infusion over 14 days [17].
Procedures
All HAT patients and healthy controls underwent a clinical
assessment, including medical history, baseline physical examina-
Author Summary
In Human African Trypanosomiasis (HAT), neurological
symptoms dominate and cardiac involvement has been
suggested. Because of increasing resistance to the
available drugs for HAT, new compounds are desperately
needed. Evaluation of cardiotoxicity is one parameter of
drug safety, but without knowledge of the baseline heart
involvement in HAT, cardiologic findings and drug-
induced alterations will be difficult to interpret. The
electrocardiogram (ECG) is a tool to evaluate cardiac
involvement and the risk of arrythmias. We analysed the
ECG of 465 HAT patients and compared them with the ECG
of 61 healthy volunteers. In HAT patients the QTc interval
was prolonged. This comprises a risk of fatal arrhythmias if
new drugs with antiarrhythmic potential will be used.
Further, repolarization changes and low voltage were
more frequent than in healthy controls. This could be
explained by an inflammation of the heart. Treatment of
HAT was associated with appearance of repolarization
changes but not with a QTc prolongation. These changes
appear to be associated with the disease, but not with a
specific drug. The main conclusion of this study is that
heart involvement is frequent in HAT and mostly well
tolerated. However, it can become relevant, if new
compounds with antiarrhythmic potential will be used.
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estimate the normal intra-individual fluctuation of ECG param-
eters, two ECG recordings per subject were obtained at baseline.
ECG changes appearing after treatment were compared to these
intra-individual ECG changes. ECG data were also obtained
during treatment in first stage HAT patients in all patients treated
with DB 289 and in 40 patients treated with pentamidine. A
clinical assessment was performed and the ECG was repeated after
completion of treatment of HAT.
All ECG tracings were interpreted by a single reader using
standardized criteria as described below. The ECG data for the
first stage HAT patients were compared to the ECG data from the
healthy controls and the second stage HAT patients.
ECG interpretation
The PQ, QRS and QT intervals were measured manually by the
principal investigator in three consecutive cycles and mean values
were calculated. Measures of the intervals were performed in lead II,
when feasible with lead V2 or I as second choice. QTc was calculated
by the Bazett formula (QTc=QT/SQR (RR). QTc shorter than
440 ms and shorter than 460 ms were considered normal for men
and women, respectively [18,19] and because a QTc longer than
500 ms is known as predictor of torsades de pointes [19] both limits
were used for the analysis. For overall ECG interpretation, the
following criteria were used. Right atrial hypertrophy (RAH):
p.2.5 mV; left atrial hypertrophy (LAH): p.120 ms; right
ventricular hypertrophy (RVH): Sokolow index right: RV1 and S
V5.1.05 mV, left ventricular hypertrophy (LVH): Cornell voltage:
R aVL and SV3 men .2.8; women .2.0;peripherallowvoltage:RI
and RII and R III,1.6 mV; PR depression: .0.8 mV; ST elevation:
.0.1 mV without notch, concave, from deep S; ST depression:
.1 mV;repolarization changes: limb leads: discordant in at least one
lead; precordial leads: negative in either V3, V4, V5 or V6. Early
repolarization type: ST elevation concave, notch at the J point,
positive T waves. Normal ECG included axis deviation, early
repolarization type [20], ST elevation .0.1 mV without notch,
concave, from deep S in precordial leads [20] and partial right bundle
brunch block (RBBB). Minor ECG changes included intraventricular
conduction delay, left or right atrial hypertrophy, isolated premature
atrial or ventricular captures and left anterior hemiblock (LAHB).
Major changes included: AV block I–III, low voltage, left and right
ventricular hypertrophy, complete bundle branch block, PR
depression, ST depression and repolarization changes.
Ethical considerations
Written informed consent (illiterates signed by fingerprint) was
obtained from all study participants. Ethical approval was granted
by the Ethics Committees of the DRC, Angola, South Sudan and
the Ethics Committee for the two cantons of Basel, Switzerland
(Ethikkomission beider Basel).
Data analysis
Data from the various studies were pooled into one single
database that contained the clinical examination, demographic data
and the ECG details. Analysis was done usingthe statistical software
package STATA 9.0 (www.stata.com). All continuous variables are
reported as mean6SD. A p-value,0.05 was considered statistically
significant. Nominal variables were compared using the X
2- test.
Comparisons between the patient groups and treatments were
performed usingthe t-test, ANOVA plusBonferronicorrection, the
Kruskal Wallis or Mann Whitney U tests where appropriate.
Results
Patient baseline characteristics are summarized in Table 1. Age
and gender distribution were similar among the disease stages, the
Table 1. Demographics and baseline description of the HAT patients and controls.
Healthy controls HAT stage 1 HAT stage 2
DB289 pentamidine melarsoprol eflornithine
n( % ) n( % ) n( % ) n( % ) n( % )
Demographics
Number of patients (Total N=526) 61 229 177 47 9
Age, mean (SD) 35 (13) 33 (13) 33 (14) 34 (12) 36 (11)
Gender (male/female) 33/28 1.2 80/149 0.5 67/110 0.6 23/24 1.0 4/5 0.8
Diagnostics
Malaria postive
a na 22 9.6 18 10.2 2 4.3 0 0.0
Filaria positive
a na 20 8.7 18 10.2 0 0.0 0 0.0
Pulse, mean (SD) 72 (11) 76 (14) 75 (13) 75 (14) 79 (16)
Pulse.100 0 10 4.4 4 2.3 1 2.1 0 0.0
Blood pressure, mean systolic (SD) 111 (13) 107 (13) 108 (15) 105 (14) 109 (24)
Malaria pre-treatment
b
Pyrimethamine/Sulfadoxine na 203 88.6 154 87.0 29 61.7 0 0.0
Amodiaquine na 4 1.7 6 3.4 0 0.0 0 0.0
Chloroquin na 2 0.9 2 1.1 0 0.0 0 0.0
Quinine na 9 3.9 7 4.0 18 38.3 9 100.0
na: not applicable, tests not done or data not available
amalaria and filaria testing are not standard and were only systematically applied in the DB289 trial series
bother anti-parasitic treatment was administered during the 3 days prior to initiation of HAT treatment
doi:10.1371/journal.pntd.0000383.t001
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Pyrimethamine-sulfadoxine (SP) was given as first line ma-
laria treatment prior to HAT treatment in all centers with the
exception of CNPP Kinshasa, where quinine was used as standard
malaria treatment due to the high level of SP resistance in
Kinshasa.
The ECG baseline intervals and characteristics are listed by
disease stage in Table 2. At baseline, QTc prolongation, which
was defined as .440 ms in men and, .460 ms in women, was
observed in 11–13% of all HAT patients. These QTc values are
considered to represent an increased risk for arrhythmia. Only one
patient had a QTc interval over 500 ms, which is associated with
an elevated risk for torsade de pointes. The proportion of major
ECG findings indicating heart involvement was significantly lower
(p-value=0.0001) in first stage (53.5%) than in second stage HAT
(69.5%). The QTc interval of HAT patients treated with
melarsoprol following malaria treatment was 412 msec in the
sulfadoxin/pyrimethamin group (SD 19) and 431 msec (SD 24) in
the quinine group.
Changes of ECG intervals and findings according to the
different treatment groups are shown in the Table 3 and 4.
During treatment, no patient in the DB289 or the pentamidine
groups developed a QTc longer than 500 ms. One patient with a
QTc longer than 500 ms at baseline had a normal QTc after
treatment. In the group of second stage patients, one patient
developed a significantly prolonged QTc interval during melar-
soprol treatment.
The development or disappearance of AV block I consisted
mostly of increases or decreases of a few milliseconds, usually from
just below to just above the upper limit of normal (200 ms) or vise
versa. During the treatment period in the DB289 group no
relevant conduction problems such as AV block II or III or
ventricular arrhythmias were seen. In the pentamidine group, two
patients developed an AV block II (Type Wenckebach), which
resolved spontaneously and was asymptomatic. One patient with
second stage HAT developed a bigeminal rhythm during
treatment with melarsoprol, which subsided after administration
of corticosteroids. There were no further significant changes in
rhythm or conduction, such as ventricular arrhythmia, appearance
of AV block III or formation of bundle branch block, observed in
ECG recordings during treatment compared to baseline or during
treatment compared to after treatment.
Table 2. ECG findings at baseline, by disease stage compared to healthy subjects.
Healthy controls HAT stage 1 HAT stage 2 p-value
N=61 N=406 N=56
ECG Intervals (msec; mean (SD))
PQ 163 (16) 159 (24) 169 (25) 0.008
c
QRS 82 (11) 80 (9) 82 (8) 0.076
QTc 403 (21) 421 (28) 423 (25) ,0.001
ab
ECG Findings (%)
atrial fibrillation/flutter 0.0 0.3 0.0 0.862
premature atrial capture 1.6 0.5 0.0 0.450
premature ventricular capture 1.6 0.7 3.6 0.285
bigeminus 0.0 0.2 0.0 0.871
AV block 1 3.3 3.7 7.1 0.449
AV block 2 0.0 0.0 0.0 1.000
RAH (Right atrial hypertrophy) 0.0 1.7 1.8 0.334
LAH (Left atrial hypertrophy) 1.6 2.5 5.4 0.394
RVH (Right ventricular hypertrophy) 3.3 5.2 3.6 0.732
LVH (Left ventricular hypertrophy) 1.6 2.0 1.7 0.977
pathologic Q 0.0 1.0 0.0 0.551
RBBB (Right bundle brunch block) 0.0 1.0 0.0 0.581
LBBB (Left bundle brunch block) 1.6 0.0 0.0 0.011
LAHB (Left anterior hemiblock) 1.6 1.7 0.0 0.584
RBBB and LAHB 0.0 0.5 1.7 0.469
repolarisation changes 6.6 35.2 32.1 ,0.001
ab
low voltage 6.7 20.0 30.4 0.005
abc
QTc prolongation
a 0 11.1 12.5 0.021
ab
minor changes 16.4 9.6 7.1 0.193
major changes 19.7 53.5 67.9 ,0.001
abc
afor male .440 msec, female .460 msec
afor healthy control vs HATstage 1 p,0.05
bfor healthy control vs HATstage 2 p,0.05
cfor HAT stage 1 vs HATstage 2 p,0.05
doi:10.1371/journal.pntd.0000383.t002
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To our knowledge this is the first study comparing ECG data of
first and second stage HAT patients and also healthy controls.
This study comprises ECG recordings of 523 participants, the
largest number of patients to date in a population with HAT.
The mean QTc interval was significantly longer in HAT
patients compared to healthy controls and increased slightly with
the progression of the disease from first to second stage. As HAT
itself was associated with QTc prolongation in more than 10% of
patients, the additional risk of a drug with potential QTc
prolongation properties has to be considered because of the risk
of fatal arrhythmias. The mean QTc interval of the eflornithine
group at baseline was longer than in the other groups. Eflornithine
was given to patients with more advanced disease. In addition,
these patients were treated with quinine before the baseline ECG
was obtained, which has a known effect on QTc [21,22].
Pretreatment with quinine in the melarsoprol group had an
additional influence on QTc prolongation. Most patients in the
other groups received SP for antimalarial treatment prior to
obtaining baseline ECG recordings, and SP has a negligible effect
on the QTc interval [23].
Cardiac involvement, as defined by major ECG alterations, was
found in more than half of the patients with first stage HAT and in
about two thirds in the second stage. Thus, ECG alterations are
not a suitable additional tool for stage determination. Repolari-
Table 3. ECG interval changes over time, by treatment.
HAT Stage 1 HAT Stage 2
DB289 pentamidine p-value melarsoprol eflornithine p-value
(N=229) (N=177) (N=47) (N=9)
PQ msec, mean (SD)
Baseline 161 (26) 157 (20) 0.091 169 (26) 170 (20) 0.914
During treatment 163 (24) 155 (26)* 0.056 nd nd na
At end of treatment 166 (25) 161 (21) 0.037 168 (26) 158 (14) 0.269
p-value 0.810 0.683 0.557 0.714
QRS msec, mean (SD)
Baseline 79 (8) 80 (9) 0.237 82 (8) 79 (11) 0.337
During treatment 79 (8) 82 (9)* 0.033 nd nd na
At end of treatment 79 (8) 81 (13) 0.057 79 (6) 77 (5) 0.353
p-value 0.699 0.939 0.483 0.155
QTc msec, mean (SD)
Baseline 422 (26) 419 (30) 0.282 420 (23) 441 (29) 0.020
During treatment 419 (27) 413 (22)* 0.185 nd nd na
At end of treatment 419 (24) 417 (24) 0.406 427 (27) 408 (23) 0.053
p-value 0.355 0.417 0.183 0.021
*ECG during treatment was only performed in n=40 patients in the pentamidine group
nd: ECGs not done
na: not applicable
doi:10.1371/journal.pntd.0000383.t003
Table 4. ECG changes during treatment (baseline vs end of treatment), by treatment.
Intraindividual changes at baseline HAT Stage 1 HAT Stage 2
DB289 Pentamidine p-value Melarsoprol DFMO
(N=526) (N=229) (N=177) (N=47) (N=9)
Repolarisation changes (%)
appearance/aggravation 1.9 5.7 4.5 0.300 29.8 44.4
disappearance/improvement 1.5 13.1 9.6 0.138 12.8 11.1
Low voltage (%)
appearance 0.2 2.2 1.7 0.363 6.4 0
disappearance 0 1.3 1.7 0.625 4.3 0
AV block I (%)
appearance 1.3 2.6 1.1 0.190 0 0
disappearance 0.8 1.3 0.6 0.872 2.1 0
doi:10.1371/journal.pntd.0000383.t004
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(11%) were the major abnormalities observed. Conduction delays,
such as bundle branch block or AV block, and pathologic Q waves
(signs of necrosis) were not found more often than in healthy
controls. An explanation of the repolarization changes and the low
voltage observed in the current study cannot be inferred from
these data. However, observations from former histological studies
showing a diffuse, interstitial lympho-mono-histiocytic infiltration
and edema in the pericardium, myocardium, and endocardium
without myocardial necrosis [2,3,24–27], support the hypothesis
that repolarization changes and low voltage represent peri-
myocarditis. The presence of pericardial involvement has been
reported in a prior echocardiographic study, where pericarditis
with pericardial effusion was demonstrated in 12% of patients [7].
In our study, repolarization changes were similar in both stages
suggesting that peri-myocarditis appears early in the disease. The
lower proportion of low voltage in first stage compared to second
stage patients (20% versus 30.5%, p=0.004) suggests that
pericardial effusion becomes more significant later in the disease.
None of the patients with first stage HAT were diagnosed with
congestive heart failure. In second stage HAT, NT-proBNP values
were significantly higher in patients than in controls [4], and 23% of
these patients had values that have been associated with an ejection
fraction of less than 40% [28]. However, the overall relatively low
NT-proBNPlevelsindicatethatmostHATpatientsprobablydidnot
have clinically relevant congestive heart failure. Thus, heart failure
appears infrequently and/or late in the disease progression of HAT.
In the following sections the effect of antiparasitic treatment to
ECG findings will be discussed. The mean PQ intervals and QTc
time did not increase during treatment of first stage disease in
either the DB289 or the pentamidine group. The appearance and
disappearance of AV block I was in the range of the normal intra-
individual fluctuation in all treatment groups. However, the
appearance of AV block II and bigeminal rhythm showed the
potential of relevant conduction problems under treatment.
Clinical case reports of conduction delays in patients with HAT
have been published. A German tourist with T.b. gambiense
infection developed transient AV block III, supraventricular
tachycardia and ventricular premature captures (class Lown IV
b) [29] and a British soldier infected with T.b. rhodesiense developed
transient second degree heart block [30]. Based on unpublished
observations, there is a minority of patients who die suddenly
without explanation and sudden cardiac death cannot be ruled out
[3]. An inflammatory process with accentuation in the conduction
system has been observed after treatment in histological studies
from HAT patients [6,31,32].
The appearance and disappearance of repolarization changes at
end of treatment were comparable between the DB289 and the
pentamidine group. These changes were significantly more
frequent than the normal intra-individual fluctuation at baseline
and could be due to an unspecific inflammatory reaction to
antiparasitic treatment or to a direct cardiotoxic effect of the
medication. Histological findings of an accentuation of the
inflammatory response have been interpreted as an immune
response to dying trypanosomes in treated HAT patients, and
could be manifested as repolarization changes [33]. A specific
cardiotoxic effect due to a single drug is unlikely to be responsible
for the observed repolarization changes, as they were observed
with all therapies studied. There was no evidence for other
etiologies such as ventricular hypertrophy or coronary heart
disease; these were young patients without angina pectoris before
and after treatment. Thus, an increase in inflammation is a likely
etiology for these transient and dynamic ECG changes that
occurred in the setting of anti-parasitic treatment.
A higher percentage of major ECG alterations after treatment
was observed in second stage patients than in first stage patients. A
higher grade of inflammation of the heart is likely to occur with
progression of the disease and explains the higher rate of
treatment-related ECG abnormalities in the eflornithine group.
The ECG alterations were well tolerated.
Limitations of this analysis were that HAT patients and healthy
controls were enrolled in different clinical trials. However, the
criteria of the interpretation of the ECG recordings were the same
in all subjects and were performed and analyzed by the same
physician.
Conclusions
Cardiac involvement, as demonstrated by ECG alterations,
appears early in the evolution of HAT and precedes CNS
involvement. As HAT itself was associated with QTc prolongation
in more than 10% of patients, the additional risk of a drug with
potential QTc prolongation properties has to be considered
because of the risk of fatal arrhythmias. DB289 and pentamidine
treatment were not associated with prolongation of the QTc
intervals and they had no obvious cardiotoxic effect. During
treatment, ECG changes such as repolarization alterations
occurred frequently, were not associated with one specific drug,
and were more common in the second stage of the disease.
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